[Glycoprotein IIb/IIIa antagonists as antithrombotic agents].
Reikvam
Asmund
A
Institutt for farmakoterapi Universitetet i Oslo Postboks 1065 Blindern 0316 Oslo. asmund.reikvam@ioks.uio.no
Madsen
Steinar
S
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D000991:Antithrombins; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex